The Defense Advanced Research Projects Agency (DARPA) Small Business Programs Office (SBPO) is issuing an SBIR/STTR Opportunity (SBO) inviting submissions of innovative research concepts in the technical domain(s) of therapeutic interfering particles as a medical countermeasure for use against viruses in humans. In particular, DARPA is interested in understanding the feasibility of Phase I Clinical Trials for Therapeutic Interfering Particles.This SBO is issued under the Broad Agency Announcement (BAA) for SBIR/STTR, HR001119S0035. All proposals in response to the technical area(s) described herein will be submitted in accordance with the instructions provided under HR001119S0035, published at: https://www.fbo.gov/spg/ODA/DARPA/CMO/HR001119S0035/listing.html. This SBO will open for proposals on June 5, 2019 and close on July 3, 2019.The purpose of Amendment 01 is to revise language in section I.b related to the DARPA Entrepreneurial Investigator Initiative and update Section I.d. Due Date/Time. Change is highlighted in yellow. Proposals will be due at 2:00 p.m. ET on July 3, 2019.
BAA Coordinator
HR001119S0035@darpa.mil